Curriculum Vitae: Panayotis Verginis

Group Title: Immune Regulation and Tolerance

CURRENT POSITION(S)

06.2024 – current **Professor Biochemistry/ Immunology**
- Department of Basic Sciences, University of Crete, Medical School

05.2020 – current **Affiliated member at Institute of Molecular Biology and Biotechnology (IMBB)**

05.2020 – 05.2024 **Associate Professor Biochemistry/Immunology**
- Department of Basic Sciences, University of Crete, Medical School

08.2020 – current **Staff Scientist, Hematology Unit, Heraklion University Hospital**

01.2016 – current **Affiliated Investigator**
University Hospital, Faculty of Medicine, Carl Gustav Carus of TU Dresden, Dresden, Germany

PREVIOUS POSITION(S)

09.2016 – 05.2020 **Investigator C' - Assistant Professor Level**
Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation, Academy of Athens

09.2012 - 08.2016 **Investigator D' – Lecturer Level**
Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation, Academy of Athens

10.2008 - 08.2012 **Research Associate**
Laboratory of Autoimmunity and Inflammation, University of Crete, Medical School and Institute of Molecular Biology and Biotechnology (IMBB)

07.2005 - 08.2008 **Post-Doctoral Fellow**
Harvard Medical School and Dana Farber Cancer Institute, Laboratory of Harald von Boehmer

EDUCATION

03.2000 - 05.2006 Doctor of Philosophy (Ph.D.), Faculty of Medicine, Memorial University of NewFoundland, Canada. Thesis title: "*Immunoregulatory mechanisms of autoimmune thyroid disease*".

09.1994 - 11.1998 Bachelor Degree (BSc), Department of Chemistry, University of Patras, Greece. Thesis title: *"Biochemical and immunological study of hydrocarbon derivatives from pathogenic microbes".*

TEACHING ACTIVITIES

2024- current Responsible for the Immunology course, Medical School University of Crete

2024- current Instructor in Biochemistry, International Program in Medicine, Medical School University of Crete

2024 – present Responsible for the Immunology course, International Program in Medicine, Medical School University of Crete

2020 - current Instructor in Biochemistry Medical School University of Crete

2014 - current Coordinator of the Immunology module (IMM216) in the "Molecular Basis of Human Disease" Graduate program at the University of Crete, Medical School, Heraklion, Crete
2016 - 2019 Lecturer – Immunology, Graduate program, University of Athens, Medical School, Athens, Greece
2012 Lecturer, Immunobiology course, Undergraduate level, Medical School, University of Crete, Heraklion, Crete (Instructor: Prof. H. Papadaki).

Major outcomes and achievements during the period

In 2024 I elected as a Professor of Biochemistry/Immunology at the Medical School, University of Crete. I had successful grant applications through national grants (ELIDEK), pharma industry and private funding (Fondation Sante) in a sum total of ~1M E

The publication record of my lab includes papers published in major peer-reviewed multi-disciplinary scientific journals with myself as a corresponding author (Varveri et al et al Nature Communications 2024, Semitekolou et al iScience 2025, Manolakou et al Science Advances 2022) as well as a contributing author (Magkouta et al Mollecular Cell 2023) This record, established my lab in the field of Immune tolerance in autoimmunity and cancer and empowered the development of important collaborations (i.e. Prof. T. Chavakis, University Clinic Carl Gustav Carus, TU Dresden; Pro. M. Netea, Radboud University Medical Center, Nijmegen, Netherlands, Prof. V. Gorgoulis, Medical School, University of Athens).

Funding 2022-2025

Title and Reference Number of the Grant: Identification of trained immunity pathways: role for immunotherapy against cancer
Funding Agency and Funding Scheme: ONO Pharmaceutics
Amount of grant for the Team: 350.000E
Start date and end date of the grant: 2022-2026

Title and Reference Number of the Grant: Deciphering the role of Cancer Associated Fibroblasts in immunotherapy resistance and tumor metastasis
Funding Agency and Funding Scheme: HFRI
Amount of grant for the Team: 320.000E
Start date and end date of the grant: 2024-2025

Title and Reference Number of the Grant: Untangling the molecular and metabolic intricacies associated with regulatory T-cell dysfunction in SLE
Funding Agency and Funding Scheme: MSD
Amount of grant for the Team: 140.000E
Start date and end date of the grant: 2024-2026

Title and Reference Number of the Grant: Prediction of response to Tofacitinib and delineation of thrombosis mechanisms based on a multi-omic JAk-STAT immune cell atlas -Aspire Grant
Funding Agency and Funding Scheme: Pfizer
Amount of grant for the Team: 80.000E
Start date and end date of the grant: 2022-2024

Title and Reference Number of the Grant: Deciphering the role of Notch signaling in regulatory T cells: a novel "checkpoint" during tumor development
Funding Agency and Funding Scheme: Fondation Sante
Amount of grant for the Team: 50.000E
Start date and end date of the grant: 2023-2024

Publications 2022-2025

As corresponding author

1. Semitekolou M, Paschalidis N, Lo Tartaro D, Tsitsopoulou A, Stamou P, Mavroudis A, Markaki E, Varveri A, Morianos I, Lavigne M, Fotsitzoudis C, Magkouta S, Dede K, Kalomenidis I, Samitas K, Potaris K, Cossarizza A, Mavroudis D, De Biasi S, **Verginis P.** Blood immunomap for prediction of responses to anti-PD-1 immunotherapy in metastatic non-small cell lung cancer. **iScience. 2025** Jun 2;28(9):112804. doi: 10.1016/j.isci.2025.112804. eCollection 2025 Sep 19.
2. Varveri A., Papadopoulou M., Papadovasilakis Z., Compeer EB, Legaki AI., Delis A., Damaskou A., Boon L., Papadogiorgaki S., Samiotaki M., Foukas P., Hatzioannou A., Alissafi T., Dustin ML., **Verginis P.** An Immunological Synapse Formation Between T Regulatory Cells and Cancer-Associated Fibroblasts Promotes Tumor Development **Nat Commun 2024** 15(1):4988. doi: 10.1038/s41467-024-49282-1.
3. Boumpas A., Papaioannou A., Bousounis P., Grigoriou M., Bergo V., Papafragkos I., Tasis A., Iskas M., Boon L., Makridakis M., Vlachou A., Gavriilaki E., Hatzioannou A., Mitroulis I., Trompouki E., **Verginis P.** PD-L1 blockade immunotherapy rewires cancer emergency myelopoiesis **Front Immunol. 2024** Oct 11;15:1386838. doi: 10.3389/fimmu.2024.1386838. eCollection 2024.
4. Papadaki G, Goutakoli P, Tiniakou I, Grün JR, Grützkau A, Pavlopoulos GA, Iliopoulos I, Bertsias G, Boumpas D, Ospelt C, Reizis B, Sidiropoulos P, **Verginis P. (**2022) IL-6 signaling Attenuates TNF-α Production by Plasmacytoid Dendritic Cells in Rheumatoid Arthritis. **J Immunol.** Nov 15;209(10):1906-1917.
5. Manolakou, T., Nikolopoulos, D., Gkikas, D., Filia. A., Samiotaki, M., Stamatakis, G., Fanouriakis, A., Politis, P., Banos, A., Alissafi, T., **Verginis, P*.,** Boumpas, D.T*. (2022). ATR-mediated DNA damage responses underlie aberrant B cell activity in systemic lupus erythematosus**. Science Advances**, 8, eabo5840. DOI: 10.1126/sciadv.abo5840
6. Papafragkos I, Grigoriou M, Boon L, Kloetgen A, Hatzioannou A, **Verginis P. (**2022) Ablation of NLRP3 inflammasome rewires MDSC function and promotes tumor regression. **Front Immunol.** Aug 10;13:889075.
7. Papafragkos I, **Verginis P.** Salty Treg cells get out of balance. **Cell Metab**. 2023 Feb 7;35(2):228-230. (Review)

As contributing author

1. Magkouta S, Veroutis D, Pousias A, Papaspyropoulos A, Pippa N, Lougiakis N, Kambas K, Lagopati N, Polyzou A, Georgiou M, Chountoulesi M, Pispas S, Foutadakis S, Pouli N, Marakos P, Kotsinas A, **Verginis P**, Valakos D, Mizi A, Papantonis A, Vatsellas G, Galanos P, Bartek J, Petty R, Serrano M, Thanos D, Roussos C, Demaria M, Evangelou K, Gorgoulis VG (2023) A fluorophore-conjugated reagent enabling rapid detection, isolation and live tracking of senescent cells. **Mol Cell**. Oct 5;83(19):3558-3573.e7. doi: 10.1016/j.molcel.2023.09.006.
2. Papaspyropoulos A, Hazapis O, Altulea A, Polyzou A, **Verginis P**, Evangelou K, Fousteri M, Papantonis A, Demaria M, Gorgoulis V (2023) Decoding of translation-regulating entities reveals heterogeneous translation deficiency patterns in cellular senescence. **Aging Cell**. Sep;22(9):e13893
3. Dionysopoulou S, Wikstrom P, Bucolo C, Romano GL, Micale V, Svensson R, Spyridakos D, Mastrodimou N, Georgakis S, **Verginis P**, Walum E, Thermos K (2023) Topically Administered NOX4 Inhibitor, GLX7013114, Is Efficacious in Treating the Early Pathological Events of Diabetic Retinopathy. **Diabetes.** May 1;72(5):638-652.
4. Georgakis S, Gkirtzimanaki K, Papadaki G, Gakiopoulou H, Drakos E, Eloranta ML, Makridakis M, Kontostathi G, Zoidakis J, Baira E, Rönnblom L, Boumpas DT, Sidiropoulos P, **Verginis P**, Bertsias G. (2021) NETs decorated with bioactive IL-33 infiltrate inflamed tissues and induce IFN-α production in patients with SLE. ***JCI Insight.*** Nov 8;6(21):e147671.